Kornimate/medical-research-clean huggingface dataset:
routine application of ostenil® in patients with gonarthrosis

Conditions: Gonarthrosis

Summary: pmcf study to observe the routine application of ostenil® in the treatment of pain and restricted mobility in degenerative and traumatic changes of the knee joint.


Eligibility criteria:
inclusion criteria: * subjects ≥ 18 years of age and in good general health condition * signed informed consent * existing ostenil® recommendation for the treatment of gonarthrosis exclusion criteria: * known hypersensitivity to one of the ostenil® components * presence of articular effusion in study-relevant knee joint * known pregnancy or lactating females * subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts * subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)
enzastaurin versus lomustine in glioblastoma

Conditions: Glioblastoma

Summary: this protocol will test the activity of enzastaurin vs. lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).


Eligibility criteria:
inclusion criteria: 1. patient presents with histologically confirmed diagnosis of brain cancer (specifically glioblastoma multiforme). 2. your cancer has returned following therapy. 3. patient may have undergone prior surgery to remove cancer. 4. patient must be able to care for self. exclusion criteria: 1. have a second type of cancer (except adequately treated basal cell carcinoma of the skin). patient who has had another cancer in the past, must be free of cancer for more than 2 years. 2. have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of entry. 3. patients receiving medication for seizures must discontinue 14 days prior to enrolling. 4. cannot be on blood thinning medication at study enrollment. 5. cannot be on other medicines to prevent cancer at study enrollment. 6. patients are not allowed to enter the study if they have previously taken enzastaurin, lomustine and/or bevacizumab.
smoking cessation intervention development for homeless youth

Conditions: Cigarette Smoking-Related Carcinoma

Summary: this trial develops a contextually tailored and optimized smoking cessation intervention and studies smoking motivations and motivations to quit smoking in homeless youth. identifying motivations for smoking and motivations to quit smoking may help researchers build a program to help homeless young people quit smoking cigarettes if desired.

primary objectives: i. establish a theoretical framework for cessation among homeless youth incorporating phase-specific capabilities and opportunities impacting motivation to engage in cessation. (multiphase optimization strategy \[most\] step 1) ii. guided by the theoretical framework for cessation among homeless youth, identify a set of cessation intervention components and assess their implementation feasibility. (most step 2) outline: most step ia: participants attend a semi-structured interview over 60 minutes to help establish theoretical model of contextually tailored smoking cessation for homeless youth. most step ib: participants complete a survey to help establish theoretical model of contextually tailored smoking cessation for homeless youth. most step ii (focus groups): participants attend focus groups to help identify a set of cessation intervention components for homeless youth and determine component acceptability and feasibility. most step ii (feasibility study): intervention components are identified and selected from focus groups. participants take part in a study to assess these components for feasibility in implementing in coordination with homeless youth services, as well as determining main effect estimates for future studies.

Eligibility criteria:
inclusion criteria: * youth who report having smoked some or every day in the past week. * youth who meet criteria for homelessness defined by the 2002 mckinney-vento act including those who lack a fixed, regular, and adequate nighttime residence; live in a welfare hotel, or place without regular sleeping accommodations; or live in a shared residence with other persons due to the loss of one's housing or economic hardship.
the effectiveness of the use of oxygen reserve index in preventing hyperoxia in the intensive care unit.

Conditions: Hyperoxia; Complication; Mechanical Ventilation Complication

Summary: oxygen therapy is the most common treatment modality for patients with hypoxemia in intensive care units, but target values for normoxemia are not clearly defined. therefore, iatrogenic hyperoxemia is a very common situation. in intensive care units, fio2 is usually adjusted according to hypoxia and hyperoxia is ignored in patients under mechanical ventilator support. even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently. continuous ori monitoring can be used for detecting and preventing hyperoxia. the ability to perform fio2 titration with ori may be an appropriate monitoring management to prevent the harmful effects of hyperoxia. in this study, it was aimed to investigate the effectiveness of ori-guided fio2 titration in preventing hyperoxia in patients undergoing mechanical ventilation in the intensive care unit and to determine the incidence of hyperoxia.

in intensive care units, fio2 is usually adjusted according to hypoxia and hyperoxia is ignored in patients under mechanical ventilator support. even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently. oxygen reserve index (ori™) (masimo corp., irvine, usa) can guide clinicians in detection of hyperoxia. ori is a parameter which can evaluate partial pressure of oxygen (pao2) rating from 0 to 1. there are growing evidences in ori that it might be helpful to reduce hyperoxia in general anesthesia. continuous ori monitoring can be used for detecting and preventing hyperoxia. the ability to perform fio2 titration with ori may be an appropriate monitoring management to prevent the harmful effects of hyperoxia. in this study, it was aimed to investigate the effectiveness of ori-guided fio2 titration in preventing hyperoxia in patients undergoing mechanical ventilation in the intensive care unit and to determine the incidence of hyperoxia.

Eligibility criteria:
inclusion criteria: * patients older than 18 years, * patients whose oxygen saturation \>97% * patients that have invasive arterial monitorization exclusion criteria: * patients younger than 18 * patients that need to be treated with high doses of vasopressors, * patients having peripheric hypoperfusion, * hemodynamically unstable patients, * patients with hemoglobinopathy, * pregnancy, * morbid obesity (bmi\>40 kg/m2), * patients with arrythmia that can result in hemodynamic instability, patients with acute coronary syndrome * acute respiratory failure or ards.

Keywords: hyperoxia fraction of inspired oxygen intensive care unit
botox® open-label treatment in pediatric upper limb spasticity

Conditions: Pediatrics; Muscle Spasticity; Cerebral Palsy; Stroke

Summary: this study will evaluate the long-term safety of botox® (botulinum toxin type a) for the treatment of pediatric upper limb spasticity.


Eligibility criteria:
inclusion criteria: * minimum weight of 10 kilograms (kg) / 22 pounds (lb) * upper limb spasticity due to cerebral palsy or stroke exclusion criteria: * muscular dystrophy, myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease * uncontrolled epilepsy * botulinum toxin therapy of any serotype for any condition within the last 3 months * history of surgical intervention of the upper limb within 1 year, or planned surgery of any limb during the study
short-term prehabilitation program : interest of on resumption of function at 2 months

Conditions: Thoracic Diseases; Urologic Diseases

Summary: this study aimed to evaluated the interest of a short-term (2 weeks) prehabilitation program compared to no prehabilitation before thoracic or urological surgery

prehabilitation is a form of global strength training, aims to improve functional capacity before surgery.this preparation compensate for its decrease due to the intervention. this process includes physical training, nutritional and psychological care. previous studies consider 4 weeks to be the ideal duration time for such program. however, extended program duration may reduce subject compliance and may not be possible for patient who can not or do not want to postponed their surgery.

Eligibility criteria:
inclusion criteria: * men or women aged 55 or over * requiring major surgery (thoracic or urological surgery: kidney or bladder) within 15 days after the completion of the inclusion assessment * having signed a consent form after a reflection period * being affiliated to a health insurance plan. exclusion criteria: * pregnant, parturient or lactating women * persons deprived of their liberty: minors or adults subject to legal protection measures or out of state to express their consent * patients (men or women) aged \<55 years; * inability to walk or initial physical assessment * inability to complete questionnaires * walk\> 450 meters in the 6 minute test * patients under guardianship or curators.

Keywords: prehabilitation
treatment of intrabony periodontal defects with enamel matrix derivatives and autogenous bone graft

Conditions: Periodontal Bone Loss; Chronic Periodontitis

Summary: the present study aimed to evaluate the effects of enamel matrix derivatives either alone or combined with autogenous bone graft applied to intrabony defects in chronic periodontitis patients on clinical/radiographic parameters and gingival crevicular fluid transforming growth factor-β1 level and, to compare with open flap debridement. our hypothesis is to test whether the use of autogenous bone graft and enamel matrix derivative combination in the treatment of intrabony periodontal defects enhance the clinical, radiographic and biochemical parameters in comparison to the use of open flap debridement alone.

the present study aimed to evaluate the effects of enamel matrix derivatives (emd) either alone or combined with autogenous bone graft (abg) applied to intrabony defects in chronic periodontitis patients on clinical/radiographic parameters and gingival crevicular fluid (gcf) transforming growth factor-β1 (tgf-β1) level and, to compare with open flap debridement (ofd). a total of 30 deep intrabony defects in 12 patients were randomly treated with emd+abg (combination group), emd alone (emd group) or ofd (control group). clinical parameters including plaque index, gingival index, bleeding on probing, probing depth, relative attachment level and recession were recorded at baseline and 6 months post-surgery. intrabony defect fill percentage was calculated on the standardized radiographs. tgf-β1 level was evaluated in gcf just before surgery and 7, 14, 30, 90, 180 days after surgery using elisa.

Eligibility criteria:
inclusion criteria: (a) no systemic diseases as diabetes mellitus or cardiovascular diseases that contraindicated periodontal surgery and could influence the outcome of the therapy; (b) no smoking (c) no medications affecting periodontal tissues; (d) no pregnancy or lactation; (e) a good level of oral hygiene (plaque index \< 1, and full mouth bleeding on probing score \<20% after initial periodontal treatment), (f) compliance with the maintenance programme and (g) presence of at least one intra-bony defect with a probing depth ≥6 mm, radiographic depth of the defect ≥3 mm as detected on the radiographs. exclusion criteria: (a) pregnancy or lactating, (b) required an antibiotic premedication, (c) received antibiotic treatment in the previous 6 months, (d) smokers, (e) whose tooth had inadequate amount of attached keratinized gingiva (\<1mm)

Keywords: autogenous bone graft chronic periodontitis enamel matrix derivatives gingival crevicular fluid periodontal flap surgery
study to evaluate the safety and preliminary efficacy of idct, a treatment for symptomatic lumbar disc degeneration

Conditions: Degenerative Disc Disease

Summary: the purpose of this study is to compare the safety and preliminary efficacy of intradiscal injections of two doses of idct (discogenic cells + sodium hyaluronate vehicle) and one sham control in subjects with chronic low back pain due to degenerative disc disease (ddd) at one lumbar level from l3 to s1.

this is a phase i/ii, randomized, double-blind, sham-controlled, parallel-group, multi-center study in subjects with single-level, symptomatic lumbar intervertebral disc degeneration (\>6 months) and unresponsive to conservative therapy for at least 3 months. the study will compare single intradiscal injections of high and low dose idct with one sham control group. 6 study visits will be completed by all subjects; screening, day 1 (injection day), week 4, week 12, week 26 and week 52. the subject will be assessed for safety and efficacy utilizing vas, odi and joabpeq questionnaires alongside radiographic evaluations. the study will have a 6 month follow-up and a 6 month extension period (total 1 year).

Eligibility criteria:
inclusion criteria: * diagnosis of early to moderate degenerative disc disease (ddd), modified pfirrmann grade 3-7. * chronic low-back pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care. * low-back pain of 40 to 90 mm on the vas * odi score of 30 to 90. exclusion criteria: * symptomatic involvement of more than one lumbar disc. * other persistent pain/nerve issues including, for example, radiculopathy, leg pain, cauda equine syndrome, etc. * fracture of the spine, previous lumbar spine surgery or previous treatment of the target disc. * evidence of dynamic instability on lumbar flexion-extension radiographs. * grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other undifferentiated spondyloarthropathy, or type iii modic changes around the target disc. * clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology. * subjects who test positive for communicable disease, have significant systemic disease, or are prone to infection. * patients who are deemed unsuitable for clinical study participation by the investigator.
management of malnutrition in oncogeriatrics

Conditions: Undernutrition; Cancer

Summary: in france, undernutrition affects almost three million people, a third of whom are over 70 (diagnosing undernutrition earlier in the elderly aged 70 and over, n.d.). in fact, 30 to 70% of hospitalized elderly patients suffer from protein-energy undernutrition (denutrition_personne_agee_2007_-_recommandations.pdf, n.d.). the nutricancer 2 study published in 2014, demonstrated that undernutrition is common among cancer patients. indeed, 39% of patients suffer from undernutrition and its prevalence depends on the type of cancer, with a predominance of esophagus, stomach and pancreas (60% to 66%), colon/rectum, ovary/uterus and lung (39% to 45%), hematological malignancies (34%), as well as prostate and breast (13% to 20%) (hébuterne et al., 2014). moreover, over the past 30 years, undernutrition has been observed in 30% to 50% of the population at the time of diagnosis and before the start of cancer treatment (boranian et al., n. d.). undernutrition is often associated with several terms such as malnutrition, anorexia, sarcopenia or cachexia, which refer to geriatric or metabolic syndromes of multifactorial origin that sometimes overlap, and are often observed in cancer patients. cancer cachexia is a metabolic syndrome associated with undernutrition of multifactorial origin (boranian et al., n.d.). its prevalence is around 50% to 80% in cancer patients and is an independent indicator of morbidity and mortality in this population (nicolini et al., 2013). undernutrition is a major health issue in elderly cancer patients. it is therefore crucial to diagnose it early, given its high prevalence in this population and the serious complications it can lead to. in 2021, the has updated its recommendations on the diagnosis of undernutrition in the elderly. the diagnosis of severe undernutrition is based on several criteria, including serum albumin levels. this is a commonly used marker of nutritional status, especially in patients with involuntary weight loss. however, it is important to note that hypoalbuminemia can be observed in many pathological conditions, including inflammatory syndromes common in cancer. therefore, interpretation of albuminemia results must take into account the patient's inflammatory status, assessed by c-reactive protein. this analysis makes it possible to distinguish undernutrition due to insufficient food intake from that associated with an inflammatory syndrome and hypercatabolism (patry \& raynaud-simon, 2010).


Eligibility criteria:
inclusion criteria: * patients aged 70 and over with a diagnosis of moderate or severe undernutrition * all patients with diagnosed cancer and ongoing cancer treatment. exclusion criteria: * patients under 70 years of age * hospitalized patients no longer undergoing anticancer treatment * all patients undergoing pre-habilitation for surgery

Keywords: malnutrition geriartric oncology aged antineoplastic agents muscle strenght
ai assisted the diagnosis of pancreatic solid lesions

Conditions: AI Assist in the Diagnosis of Pancreatic Solid Lesions

Summary: solid lesions of the pancreas mainly include tumor and non tumor lesions. more than 90% of pancreatic tumor lesions are pancreatic cancer, which is characterized by high mortality and poor prognosis and requires surgical treatment; non-tumor lesions of the pancreas are mainly inflammatory lesions, which usually do not require surgical treatment, but can be treated with drugs. the common ones are chronic pancreatitis and autoimmune pancreatitis, with a good prognosis. clinically, the differential diagnosis between them is very difficult. multi-disciplinary diagnosis and treatment of mdt makes our understanding of pancreatic diseases increasingly rich and in-depth. from disease diagnosis to preoperative evaluation and curative effect evaluation, non-invasive imaging involves almost every link under mdt mode. in view of this, improving the differential diagnosis of pancreatic solid space-occupying lesions on imaging will be more conducive to the diagnosis and treatment under mdt mode, so new technologies such as artificial intelligence should be considered. our goal is to develop a clinically applicable artificial intelligence system, which uses multiple modes to simulate the routine clinical workflow and assist in the diagnosis of benign and malignant pancreatic solid space-occupying lesions.

the diagnosis of solid pancreatic lesions is challenging, mdt is a very effective method, but it has a certain misdiagnosis rate. this is a multi-center, prospective and observational clinical study. our goal is to develop a clinically applicable artificial intelligence system. on the one hand, our artificial intelligence based on clinical data+ct imaging images can assist mdt doctors to diagnose the nature of pancreatic space-occupying lesions and reduce misdiagnosis; on the other hand, if a patient needs eus-fna puncture, the multimodal artificial intelligence system based on clinical data+ct+eus developed by us can help mdt doctors understand the nature of pancreatic space-occupying lesions and reduce the probability of misdiagnosis or secondary puncture.

Eligibility criteria:
inclusion criteria: * pancreatic solid mass in ct and eus exclusion criteria: * insufficient imaging quality of ct or eus * endoscopic ultrasound non accessible lesions
applicability clinic of cement portland structural white in endodontic surgery

Conditions: Mandibular Hypoplasia

Summary: thirty teeth twelve patients, two female and a male, who had persistent periradicular lesions were selected to participate in this study. the lesions were diagnosed with cone-beam computed tomography (cone-beam ct; model i-cat 17-19, imaging sciences international llc).in patients with two teeth to be treated, a tooth was retroobturado with pbea cement, (experiment) and another tooth was retroobturado with mta cement (control). there was significance for the two cements on the repair of wounds. key words: apicoectomy; oral surgery; biocompatible materials; dental cements; translational medical research

objective: to evaluate the clinical applicability of structural portland white cement additive in retrofilling surgeries. method: persistent apical periodontitis 30 teeth of 12 patients were diagnosed by computed tomography ct, cone beam. each of them had from two to four compromised teeth. the endodontic surgery were performed and the teeth were retrofilling each patient had a retrofilling tooth with cement mineral trioxide aggregate (mta) control and other tooth with white portland cement structural additive (pbea) experiment. when the patient presented four teeth with injury, two were retrofilling with mta and two portland cement with structural white cement additive. six months after surgery, there were new scans to evaluate the repair or not the wounds.

Eligibility criteria:
inclusion criteria: * patients were diagnosed by computed tomography ct, cone beam * each of them had from two to four compromised teeth exclusion criteria: * patients who did not return for review after six months

Keywords: apicoectomy oral surgery biocompatible materials dental cements translational medical research